Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib

Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):720-723. doi: 10.1016/j.clml.2020.06.014. Epub 2020 Jun 25.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.

Keywords: Allogeneic stem cell transplantation; COVID-19; Graft-versus-host disease; Immunocompromised; JAK inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Betacoronavirus / immunology*
  • Betacoronavirus / isolation & purification
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / immunology
  • Coronavirus Infections / virology
  • Graft vs Host Disease / drug therapy*
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / immunology
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immunocompromised Host
  • Lymphoma, T-Cell / immunology
  • Lymphoma, T-Cell / therapy
  • Male
  • Middle Aged
  • Nitriles
  • Pandemics
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • SARS-CoV-2
  • Severity of Illness Index
  • Transplantation, Homologous / adverse effects
  • Treatment Outcome

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib